Upstream Bio, Inc. (UPB)
| Market Cap | 354.92M -61.6% |
| Revenue (ttm) | 3.16M +16.0% |
| Net Income | -156.50M |
| EPS | -2.89 |
| Shares Out | 54.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 515,756 |
| Open | 6.62 |
| Previous Close | 6.55 |
| Day's Range | 6.41 - 6.98 |
| 52-Week Range | 5.85 - 33.68 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 33.50 (+416.98%) |
| Earnings Date | Aug 11, 2026 |
About UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Financial Performance
In 2025, Upstream Bio's revenue was $2.85 million, an increase of 20.42% compared to the previous year's $2.37 million. Losses were -$143.44 million, 87.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for UPB stock is "Buy." The 12-month stock price target is $33.5, which is an increase of 416.98% from the latest price.
News
Upstream Bio unveils Phase 3 plans for Verekitug in asthma, nasal polyps
Upstream Bio (UPB) announced its pivotal Phase 3 development plans for Verekitug in severe asthma and chronic rhinosinusitis with nasal polyps. Verekitug is the only known antagonist currently in clin...
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indi...
Upstream Bio price target lowered to $25 from $43 at Truist
Truist analyst Danielle Brill lowered the firm’s price target on Upstream Bio (UPB) to $25 from $43 and keeps a Buy rating on the shares after its Q2 results. The…
Upstream Bio price target raised to $9 from $8 at JPMorgan
JPMorgan raised the firm’s price target on Upstream Bio (UPB) to $9 from $8 and keeps a Neutral rating on the shares.
Upstream Bio price target lowered to $25 from $43 at Truist
Truist lowered the firm’s price target on Upstream Bio (UPB) to $25 from $43 and keeps a Buy rating on the shares. Following the Q2 business update, the firm sees…
Upstream Bio reports Q2 revenue $773,000, consensus $377,250
“We continued to make progress toward the initiation of our Phase 3 trials in severe asthma and CRSwNP in the first quarter of 2027. Our End-of-Phase 2 interactions with the…
Upstream Bio Earnings release: Q2 2026
Upstream Bio released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Upstream Bio Quarterly report: Q2 2026
Upstream Bio has published its Q2 2026 quarterly earnings report on August 11, 2026.
Upstream Bio Slides: Corporate presentation
Upstream Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Upstream Bio management to meet with Piper Sandler
Meeting to be held in New York on June 23 hosted by Piper Sandler.
Upstream Bio presents new responder analyses from VIBRANT trial of verekitug
Upstream Bio (UPB) presented new responder analyses from the Phase 2 VIBRANT trial of verekitug in participants with chronic rhinosinusitis with nasal polyps. The findings were presented during an ora...
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 65 classes of mortgage pass-through notes from OBX 2026-AHC2 Trust, a prime agency-eligible RMBS transaction sponso...
Upstream Bio downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Upstream Bio (UPB) to Neutral from Overweight with a price target of $8, down from $35. There are other thymic stromal lymphopoietin competitors in asthma that will be…
Upstream Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Verekitug, a TSLP receptor-targeting antibody, showed strong phase II results in severe asthma and CRSwNP, supporting quarterly dosing and broad efficacy. Phase III trials in both indications are set for early next year, with a robust cash runway and plans for pipeline expansion.
Upstream Bio Transcript: AGM 2026
The meeting confirmed a quorum, elected two directors for three-year terms, and ratified the appointment of PricewaterhouseCoopers as auditor for 2026. All proposals were approved, with results to be filed in a Form 8-K.
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield initiated coverage of Upstream Bio (UPB) with a Buy rating and $36 price target The company’s lead biologic candidate verekitug reflects a novel antibody antag...
Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug
Upstream Bio (UPB) presented new data from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps. The data, presented in two posters at the…
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and c...
Upstream Bio price target lowered to $50 from $51 at Mizuho
Mizuho lowered the firm’s price target on Upstream Bio (UPB) to $50 from $51 and keeps an Outperform rating on the shares. The firm updated the company’s model post the…
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for mi...
Upstream Bio Earnings release: Q1 2026
Upstream Bio released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Upstream Bio Quarterly report: Q1 2026
Upstream Bio has published its Q1 2026 quarterly earnings report on May 13, 2026.